Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious medical conditions. The company leverages proprietary technology platforms to maintain a robust pipeline across multiple therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Its value proposition is built on a high-productivity research engine that translates human genetics and antibody technologies into market-leading therapies.
Financials
Based on Q1 2026 filing
Revenue
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Ophthalmology
primaryFocuses on treating serious eye diseases, primarily through vascular endothelial growth factor (VEGF) inhibition. This segment includes the company's most significant revenue-generating products for retinal conditions.
EYLEA HD, EYLEA
Retina specialists, Ophthalmologists, Hospitals
Immunology & Inflammation
majorDevelops therapies for allergic and inflammatory diseases by targeting specific immune pathways. This segment features a major global blockbuster therapy used across multiple respiratory and dermatological indications.
Dupixent, Kevzara, Itepekimab
Dermatologists, Allergists, Pulmonologists, Rheumatologists
Oncology
moderateConcentrates on cancer treatments including PD-1 inhibitors and bispecific antibodies. The portfolio covers both solid tumors and hematologic malignancies.
Libtayo, Ordspono, Lynozyfic, ZALTRAP
Oncologists, Hematologists, Cancer treatment centers
Rare Diseases & Internal Medicine
moderateAddresses specialized conditions including genetic disorders, cardiovascular risks, and infectious diseases through targeted antibody and gene-silencing technologies.
Praluent, Evkeeza, Inmazeb, Veopoz, ARCALYST
Cardiologists, Geneticists, Specialized clinics, Government health agencies
Segment Financials
Reportable Segment — Reimbursement of research and development expenses by collaborators
View metricBusiness Overview
Competitive Position
A leading biotechnology innovator with a dominant position in the retinal disease market and a major global presence in immunology through strategic partnerships.
Geographies
United States, European Union, Japan
Customer Segments
Specialty healthcare providers, Government healthcare programs, Private insurers
Upstream Dependencies
Raw material suppliers for biologics, Specialized laboratory equipment providers, Contract research organizations (CROs), Genetic data repositories
Downstream Customers
Wholesale drug distributors, Specialty pharmacies, Hospitals and clinics, Government health programs (Medicare/Medicaid)
Competitors & Partners
Competitors
Partners
Sanofi
SNY
Major collaborator for Dupixent, Kevzara, and Praluent commercialization and development.
Intellia Therapeutics
NTLA
Development partner for CRISPR/Cas9 gene-editing therapies like Nex-z.
Alnylam Pharmaceuticals
ALNY
Collaborator on RNAi therapeutics including Rapirosiran and ALN-ANG3.
Kiniksa Pharmaceuticals International, plc
KNSA
Licensee recording net sales for ARCALYST.
Subsidiaries
Decibel Therapeutics
Acquired subsidiary focused on gene therapies for hearing loss (DB-OTO).
Regeneron Pharmaceuticals FAQ
Common questions about Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious medical conditions. The company leverages proprietary technology platforms to maintain a robust pipeline across multiple therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Its value proposition is built on a high-productivity research engine that translates human genetics and antibody technologies into market-leading therapies.
Regeneron Pharmaceuticals (REGN) has a market capitalization of $67.0B and trades on NASDAQ.
Regeneron Pharmaceuticals generated $14.9B in trailing twelve-month revenue with net income of $4.4B, representing a net margin of 29.6%, with free cash flow of $4.1B. These figures are based on the Q1 2026 filing.
Regeneron Pharmaceuticals's key competitors include Amgen, Merck & Co., Bristol-Myers Squibb Co., and others. These companies compete in similar markets and product categories.
Regeneron Pharmaceuticals has approximately 13,450 employees.